In Vivo Model Development for Sjogren Syndrome

Protheragen offers a comprehensive in vivo model development service for Sjogren Syndrome, supporting preclinical research and therapeutic discovery. Our platform provides access to a wide range of validated murine models that accurately recapitulate key aspects of human Sjogren Syndrome, enabling robust evaluation of candidate therapeutics and mechanistic studies.

Animal models are essential tools in Sjogren Syndrome research, providing critical insights into disease pathogenesis and facilitating the preclinical assessment of novel interventions. Protheragen utilizes Mus musculus (mouse) as the primary species, with a variety of strains including C57BL/6, C57BL/6J, NFS/sld, and NOD.B10, each selected for their genetic relevance, immune system characteristics, and well-established use in autoimmunity research. These models mimic the immunopathology, glandular dysfunction, and systemic features observed in human Sjogren Syndrome, thus serving as translationally relevant platforms for both basic and translational research.

Chemically-Induced Models

Chemically-induced models employ agents such as vadimezan or dinitrophenol to trigger immune-mediated dysfunction and inflammation within the salivary glands, replicating hallmark features of Sjogren Syndrome. The methodology involves systemic or local administration of these chemicals to susceptible mouse strains, leading to glandular injury and immune activation. Key advantages include rapid disease induction, reproducibility, and suitability for screening drug efficacy. These models are primarily used for evaluating anti-inflammatory compounds, studying mechanisms of glandular destruction, and testing interventions targeting acute disease phases.

Biological Agent-Induced Models

These models utilize biological agents—such as immunodominant peptides (MART-1, gp100, survivin, tyrosinase) combined with adjuvants (GM-CSF, Freund's adjuvant, CpG7909)—to induce autoimmunity and glandular pathology. The methodology typically involves immunization protocols that promote robust, antigen-specific immune responses, resulting in lymphocytic infiltration and secretory dysfunction. Advantages include the ability to dissect antigen-specific immune mechanisms and mimic chronic disease progression. These models are invaluable for studying immunopathogenesis, evaluating antigen-targeted therapies, and understanding the role of specific immune pathways in Sjogren Syndrome.

Genetic and Transgenic Models

Genetic and transgenic models encompass knockout (e.g., COX2-deficient NOD.B10 mice), transgenic (CD40, CD40LG), and thymectomy-induced systems (NFS/sld mice). These models are generated via gene editing, transgenic expression, or surgical intervention to disrupt immune tolerance and promote autoimmunity. The main advantages are their ability to recapitulate spontaneous disease onset, chronicity, and genetic predisposition observed in human patients. These models are ideal for investigating genetic risk factors, long-term therapeutic interventions, and the impact of immune regulation on disease progression.

Protheragen delivers a full-spectrum solution for Sjogren Syndrome animal modeling, from model selection and customization to comprehensive in vivo study execution. Our services include model induction, therapeutic administration, and multi-parametric efficacy evaluation. Key endpoints measured encompass salivary flow rates, histopathological scoring of glandular tissues, lymphocytic infiltration, serological autoantibody profiling, cytokine quantification, and molecular biomarker analysis. We offer advanced analytical capabilities such as immunohistochemistry, flow cytometry, ELISA, and gene expression profiling. All procedures are conducted under stringent quality control protocols, ensuring reproducibility, scientific rigor, and compliance with ethical standards.

Partnering with Protheragen ensures access to scientifically validated, customizable Sjogren Syndrome animal models and expert-driven study design. Our integrated approach accelerates the translation of your therapeutic candidates from bench to bedside, providing actionable data and regulatory-ready documentation. Contact us today to discuss your project goals and advance your Sjogren Syndrome research with confidence.